{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:30:25Z","timestamp":1760239825400,"version":"build-2065373602"},"reference-count":169,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.hoc.2012.07.003","type":"journal-article","created":{"date-parts":[[2012,8,28]],"date-time":"2012-08-28T14:30:18Z","timestamp":1346164218000},"page":"993-1015","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Genotype-Phenotype Interactions in the Myeloproliferative Neoplasms"],"prefix":"10.1016","volume":"26","author":[{"given":"Anna L.","family":"Godfrey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony R.","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.hoc.2012.07.003_bib1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"issue":"7037","key":"10.1016\/j.hoc.2012.07.003_bib2","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A\u00a0unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"9464","key":"10.1016\/j.hoc.2012.07.003_bib3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.hoc.2012.07.003_bib4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"17","key":"10.1016\/j.hoc.2012.07.003_bib5","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A\u00a0gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.hoc.2012.07.003_bib6","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1073\/pnas.0601462103","article-title":"The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation","volume":"103","author":"Jamieson","year":"2006","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"1","key":"10.1016\/j.hoc.2012.07.003_bib7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2006-03-007146","article-title":"Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis","volume":"109","author":"Delhommeau","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2012.07.003_bib8","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2006-04-017392","article-title":"Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera","volume":"108","author":"Ishii","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2012.07.003_bib9","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2006-10-054940","article-title":"The JAK2 V617F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera","volume":"110","author":"Dupont","year":"2007","journal-title":"Blood"},{"issue":"49","key":"10.1016\/j.hoc.2012.07.003_bib10","doi-asserted-by":"crossref","first-page":"47954","DOI":"10.1074\/jbc.M205156200","article-title":"The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction","volume":"277","author":"Saharinen","year":"2002","journal-title":"J\u00a0Biol Chem"},{"issue":"4","key":"10.1016\/j.hoc.2012.07.003_bib11","doi-asserted-by":"crossref","first-page":"e18522","DOI":"10.1371\/journal.pone.0018522","article-title":"Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation","volume":"6","author":"Sanz","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.hoc.2012.07.003_bib12","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1371\/journal.pone.0000018","article-title":"Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F","volume":"1","author":"Zaleskas","year":"2006","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.hoc.2012.07.003_bib13","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.cellsig.2011.01.009","article-title":"Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation","volume":"23","author":"Kamishimoto","year":"2011","journal-title":"Cell Signal"},{"issue":"8","key":"10.1016\/j.hoc.2012.07.003_bib14","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1074\/jbc.M109.040733","article-title":"STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant","volume":"285","author":"Funakoshi-Tago","year":"2010","journal-title":"J\u00a0Biol Chem"},{"issue":"15","key":"10.1016\/j.hoc.2012.07.003_bib15","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/blood-2011-03-345215","article-title":"Critical requirement for Stat5 in a mouse model of polycythemia vera","volume":"119","author":"Yan","year":"2011","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.hoc.2012.07.003_bib16","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1182\/blood-2011-12-397554","article-title":"Essential role for Stat5a\/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice","volume":"119","author":"Walz","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2012.07.003_bib17","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2005-10-009514","article-title":"Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells","volume":"108","author":"Garcon","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2012.07.003_bib18","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1365-2141.2008.07526.x","article-title":"Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category?","volume":"144","author":"Wardrop","year":"2009","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.hoc.2012.07.003_bib19","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2005-05-1898","article-title":"The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia","volume":"106","author":"Levine","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2012.07.003_bib20","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"issue":"49","key":"10.1016\/j.hoc.2012.07.003_bib21","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.1038\/sj.onc.1203925","article-title":"Janus kinases: components of multiple signaling pathways","volume":"19","author":"Rane","year":"2000","journal-title":"Oncogene"},{"issue":"9501","key":"10.1016\/j.hoc.2012.07.003_bib22","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.hoc.2012.07.003_bib23","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/sj.leu.2403902","article-title":"Clinical implications of the JAK2\u00a0V617F mutation in essential thrombocythemia","volume":"19","author":"Antonioli","year":"2005","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.hoc.2012.07.003_bib24","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","article-title":"JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance","volume":"131","author":"Wolanskyj","year":"2005","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2012.07.003_bib25","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2005.05858.x","article-title":"The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia","volume":"132","author":"Cheung","year":"2006","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.hoc.2012.07.003_bib26","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/cncr.22663","article-title":"Clinical correlates of JAK2V617F allele burden in essential thrombocythemia","volume":"109","author":"Kittur","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2012.07.003_bib27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.leukres.2008.06.006","article-title":"Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia","volume":"33","author":"Dahabreh","year":"2009","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.hoc.2012.07.003_bib28","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.21645","article-title":"The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera","volume":"106","author":"Tefferi","year":"2006","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2012.07.003_bib29","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2012.07.003_bib30","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2008.113","article-title":"Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal","volume":"22","author":"Vannucchi","year":"2008","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.hoc.2012.07.003_bib31","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.hoc.2012.07.003_bib32","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A\u00a0prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.hoc.2012.07.003_bib33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.leukres.2010.06.017","article-title":"JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy","volume":"35","author":"Silver","year":"2011","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.hoc.2012.07.003_bib34","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2006-01-013540","article-title":"The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera","volume":"108","author":"Lippert","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2012.07.003_bib35","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/sj.leu.2404724","article-title":"Bone marrow JAK2V617F allele burden\u00a0and clinical correlates in polycythemia vera","volume":"21","author":"Tefferi","year":"2007","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.hoc.2012.07.003_bib36","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.exphem.2008.05.006","article-title":"Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens","volume":"36","author":"Moliterno","year":"2008","journal-title":"Exp Hematol"},{"issue":"9","key":"10.1016\/j.hoc.2012.07.003_bib37","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.exphem.2009.06.006","article-title":"JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera","volume":"37","author":"Carobbio","year":"2009","journal-title":"Exp Hematol"},{"issue":"1","key":"10.1016\/j.hoc.2012.07.003_bib38","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3324\/haematol.11653","article-title":"Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia","volume":"93","author":"Antonioli","year":"2008","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.hoc.2012.07.003_bib39","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/sj.leu.2404861","article-title":"Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow","volume":"22","author":"Larsen","year":"2008","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.hoc.2012.07.003_bib40","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1182\/blood-2006-04-018259","article-title":"Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia","volume":"108","author":"Scott","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2012.07.003_bib41","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1600-0609.2007.00960.x","article-title":"The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis\u2013impact on disease phenotype","volume":"79","author":"Larsen","year":"2007","journal-title":"Eur J Haematol"},{"issue":"9","key":"10.1016\/j.hoc.2012.07.003_bib42","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1634\/stemcells.2007-0175","article-title":"Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes","volume":"25","author":"Pardanani","year":"2007","journal-title":"Stem Cells"},{"issue":"7","key":"10.1016\/j.hoc.2012.07.003_bib43","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3324\/haematol.2009.014407","article-title":"Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders","volume":"95","author":"Stein","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2012.07.003_bib44","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2012-05-431791","article-title":"JAK2V617F-homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone","author":"Godfrey","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2012.07.003_bib45","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.exphem.2006.12.007","article-title":"In\u00a0vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele","volume":"35","author":"Gaikwad","year":"2007","journal-title":"Exp Hematol"},{"issue":"1","key":"10.1016\/j.hoc.2012.07.003_bib46","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood-2010-12-327593","article-title":"Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms","volume":"118","author":"Anand","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2012.07.003_bib47","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1242\/dmm.006817","article-title":"Mouse models of myeloproliferative neoplasms: JAK of all grades","volume":"4","author":"Li","year":"2011","journal-title":"Dis Model Mech"},{"issue":"11","key":"10.1016\/j.hoc.2012.07.003_bib48","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","article-title":"Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model","volume":"107","author":"Wernig","year":"2006","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2012.07.003_bib49","doi-asserted-by":"crossref","first-page":"11156","DOI":"10.1158\/0008-5472.CAN-06-2210","article-title":"Characterization of murine JAK2V617F-positive myeloproliferative disease","volume":"66","author":"Bumm","year":"2006","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.hoc.2012.07.003_bib50","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","article-title":"JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis","volume":"108","author":"Lacout","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2012.07.003_bib51","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.leu.2405043","article-title":"Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F","volume":"22","author":"Shide","year":"2008","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.hoc.2012.07.003_bib52","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1182\/blood-2007-05-091579","article-title":"Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice","volume":"111","author":"Xing","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2012.07.003_bib53","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice","volume":"111","author":"Tiedt","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2012.07.003_bib54","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells","volume":"17","author":"Mullally","year":"2010","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.hoc.2012.07.003_bib55","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2009-12-257063","article-title":"Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice","volume":"116","author":"Marty","year":"2010","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.hoc.2012.07.003_bib56","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","article-title":"Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease","volume":"115","author":"Akada","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2012.07.003_bib57","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2009-12-259747","article-title":"JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia","volume":"116","author":"Li","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2012.07.003_bib58","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1182\/blood-2005-05-1889","article-title":"Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2","volume":"106","author":"Kralovics","year":"2005","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.hoc.2012.07.003_bib59","first-page":"3940","article-title":"Gene expression profiling in polycythemia vera using cDNA microarray technology","volume":"63","author":"Pellagatti","year":"2003","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.hoc.2012.07.003_bib60","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ccr.2010.10.013","article-title":"Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling","volume":"18","author":"Chen","year":"2010","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.hoc.2012.07.003_bib61","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.hoc.2012.07.003_bib62","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.hoc.2012.07.003_bib63","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","article-title":"Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders","volume":"111","author":"Pietra","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2012.07.003_bib64","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3324\/haematol.13223","article-title":"Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera","volume":"94","author":"Schnittger","year":"2009","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.hoc.2012.07.003_bib65","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1182\/blood-2007-09-111971","article-title":"Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations","volume":"111","author":"Li","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2012.07.003_bib66","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","article-title":"Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.hoc.2012.07.003_bib67","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.leukres.2009.06.017","article-title":"JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms","volume":"34","author":"Siemiatkowska","year":"2010","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.hoc.2012.07.003_bib68","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1309\/AJCPK7KGOWPHYWM0","article-title":"High percentage of JAK2 exon 12 mutation in Asian patients with polycythemia vera","volume":"134","author":"Yeh","year":"2010","journal-title":"Am J Clin Pathol"},{"issue":"12","key":"10.1016\/j.hoc.2012.07.003_bib69","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.3324\/haematol.12011","article-title":"JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis","volume":"92","author":"Martinez-Aviles","year":"2007","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.hoc.2012.07.003_bib70","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1365-2141.2008.07223.x","article-title":"Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F-negative polycythaemia vera patients","volume":"142","author":"Kouroupi","year":"2008","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.hoc.2012.07.003_bib71","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.exphem.2007.08.010","article-title":"Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis","volume":"35","author":"Williams","year":"2007","journal-title":"Exp Hematol"},{"issue":"12","key":"10.1016\/j.hoc.2012.07.003_bib72","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3324\/haematol.11643","article-title":"The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels","volume":"92","author":"Percy","year":"2007","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.hoc.2012.07.003_bib73","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.leukres.2008.01.002","article-title":"Low frequency of JAK2 exon 12 mutations in classic and atypical CMPDs","volume":"32","author":"Ormazabal","year":"2008","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.hoc.2012.07.003_bib74","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1365-2141.2008.07180.x","article-title":"Loss of the JAK2 intramolecular auto-inhibition mechanism is predicted by structural modelling of a novel exon 12 insertion mutation in a case of idiopathic erythrocytosis","volume":"142","author":"Albiero","year":"2008","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2012.07.003_bib75","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/sj.leu.2404971","article-title":"Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients","volume":"22","author":"Butcher","year":"2008","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.hoc.2012.07.003_bib76","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1182\/blood-2007-05-092502","article-title":"A\u00a0new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis","volume":"110","author":"Colaizzo","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2012.07.003_bib77","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2012.07.003_bib78","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/ajh.21357","article-title":"Isolated erythrocytosis in V617F negative patients with JAK2 exon 12 mutations: report of a new mutation","volume":"84","author":"Bernardi","year":"2009","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.hoc.2012.07.003_bib79","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2141.2007.06806.x","article-title":"Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera","volume":"139","author":"Scott","year":"2007","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2012.07.003_bib80","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1182\/blood-2010-08-270033","article-title":"How I treat essential thrombocythemia","volume":"117","author":"Beer","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2012.07.003_bib81","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood-2008-01-134114","article-title":"JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders","volume":"112","author":"Plo","year":"2008","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.hoc.2012.07.003_bib82","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1056\/NEJMoa0804953","article-title":"Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders","volume":"359","author":"Zhao","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.hoc.2012.07.003_bib83","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1182\/blood-2005-12-013748","article-title":"Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation","volume":"108","author":"Campbell","year":"2006","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.hoc.2012.07.003_bib84","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","article-title":"Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm","volume":"115","author":"Beer","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2012.07.003_bib85","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.hoc.2012.07.003_bib86","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2012.07.003_bib87","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/leu.2008.137","article-title":"New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1\/S-phase transition","volume":"22","author":"Chaligne","year":"2008","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.hoc.2012.07.003_bib88","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2012.07.003_bib89","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1365-2141.2010.08083.x","article-title":"Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis","volume":"149","author":"Boyd","year":"2010","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2012.07.003_bib90","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3324\/haematol.13224","article-title":"Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis","volume":"94","author":"Schnittger","year":"2009","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.hoc.2012.07.003_bib91","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1182\/blood-2003-10-3471","article-title":"Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin","volume":"103","author":"Ding","year":"2004","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2012.07.003_bib92","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1200\/JCO.2006.08.6884","article-title":"Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia","volume":"25","author":"Teofili","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2012.07.003_bib93","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3324\/haematol.2010.034793","article-title":"Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms","volume":"96","author":"Pietra","year":"2011","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.hoc.2012.07.003_bib94","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.exphem.2008.06.006","article-title":"Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray","volume":"36","author":"Kawamata","year":"2008","journal-title":"Exp Hematol"},{"issue":"3","key":"10.1016\/j.hoc.2012.07.003_bib95","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1182\/blood-2008-01-135897","article-title":"Characteristics and clinical correlates of MPL 515W>L\/K mutation in essential thrombocythemia","volume":"112","author":"Vannucchi","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2012.07.003_bib96","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2007.06565.x","article-title":"Anaemia characterises patients with myelofibrosis harbouring Mpl mutation","volume":"137","author":"Guglielmelli","year":"2007","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.hoc.2012.07.003_bib97","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1365-2141.2008.07560.x","article-title":"Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones","volume":"144","author":"Beer","year":"2009","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2012.07.003_bib98","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood-2008-10-183558","article-title":"Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor","volume":"115","author":"Pecquet","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2012.07.003_bib99","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2007-05-089003","article-title":"Evidence for MPL W515L\/K mutations in hematopoietic stem cells in primitive myelofibrosis","volume":"110","author":"Chaligne","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2012.07.003_bib100","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.hoc.2012.07.003_bib101","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","article-title":"New mutations and pathogenesis of myeloproliferative neoplasms","volume":"118","author":"Vainchenker","year":"2011","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.hoc.2012.07.003_bib102","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.hoc.2012.07.003_bib103","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","article-title":"TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.hoc.2012.07.003_bib104","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2009-03-210039","article-title":"Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies","volume":"114","author":"Abdel-Wahab","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2012.07.003_bib105","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/leu.2009.169","article-title":"Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias","volume":"24","author":"Couronne","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.hoc.2012.07.003_bib106","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/0008-5472.CAN-09-3783","article-title":"Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias","volume":"70","author":"Abdel-Wahab","year":"2010","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.hoc.2012.07.003_bib107","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/leu.2009.59","article-title":"Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS\/MPN and AML","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.hoc.2012.07.003_bib108","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.1182\/blood-2009-02-205690","article-title":"Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic\/myeloproliferative neoplasms","volume":"113","author":"Jankowska","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2012.07.003_bib109","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3324\/haematol.2009.011205","article-title":"TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia","volume":"94","author":"Kosmider","year":"2009","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.hoc.2012.07.003_bib110","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood-2009-07-234484","article-title":"Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission","volume":"116","author":"Nibourel","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2012.07.003_bib111","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","article-title":"TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis","volume":"20","author":"Quivoron","year":"2011","journal-title":"Cancer cell"},{"issue":"14","key":"10.1016\/j.hoc.2012.07.003_bib112","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1182\/blood-2011-02-339747","article-title":"TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics","volume":"118","author":"Chou","year":"2011","journal-title":"Blood"},{"issue":"7325","key":"10.1016\/j.hoc.2012.07.003_bib113","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nature09586","article-title":"Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2","volume":"468","author":"Ko","year":"2010","journal-title":"Nature"},{"issue":"35","key":"10.1016\/j.hoc.2012.07.003_bib114","doi-asserted-by":"crossref","first-page":"14566","DOI":"10.1073\/pnas.1112317108","article-title":"Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice","volume":"108","author":"Ko","year":"2011","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"17","key":"10.1016\/j.hoc.2012.07.003_bib115","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1182\/blood-2010-12-325241","article-title":"Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies","volume":"118","author":"Li","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2012.07.003_bib116","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","article-title":"Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation","volume":"20","author":"Moran-Crusio","year":"2011","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.hoc.2012.07.003_bib117","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1182\/blood-2010-12-324707","article-title":"Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors","volume":"118","author":"Pronier","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2012.07.003_bib118","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2009-09-245381","article-title":"Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms","volume":"115","author":"Schaub","year":"2010","journal-title":"Blood"},{"issue":"7078","key":"10.1016\/j.hoc.2012.07.003_bib119","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nature04431","article-title":"The Polycomb group protein EZH2 directly controls DNA methylation","volume":"439","author":"Vire","year":"2006","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.hoc.2012.07.003_bib120","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat Genet"},{"issue":"19","key":"10.1016\/j.hoc.2012.07.003_bib121","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2012.07.003_bib122","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2011.58","article-title":"Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms","volume":"25","author":"Abdel-Wahab","year":"2011","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.hoc.2012.07.003_bib123","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/ng.620","article-title":"Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes","volume":"42","author":"Nikoloski","year":"2010","journal-title":"Nat Genet"},{"issue":"14","key":"10.1016\/j.hoc.2012.07.003_bib124","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood-2010-10-311019","article-title":"Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A","volume":"118","author":"Jankowska","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2012.07.003_bib125","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/leu.2010.167","article-title":"Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies","volume":"24","author":"Makishima","year":"2010","journal-title":"Leukemia"},{"issue":"7295","key":"10.1016\/j.hoc.2012.07.003_bib126","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nature08966","article-title":"Histone H2A deubiquitinase activity of the polycomb repressive complex PR-DUB","volume":"465","author":"Scheuermann","year":"2010","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.hoc.2012.07.003_bib127","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/leu.2009.141","article-title":"Mutations of ASXL1 gene in myeloproliferative neoplasms","volume":"23","author":"Carbuccia","year":"2009","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.hoc.2012.07.003_bib128","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2141.2009.07697.x","article-title":"Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia","volume":"145","author":"Gelsi-Boyer","year":"2009","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2012.07.003_bib129","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.2010.08381.x","article-title":"ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia","volume":"151","author":"Gelsi-Boyer","year":"2010","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1016\/j.hoc.2012.07.003_bib130","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1200\/JCO.2010.33.4938","article-title":"Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes","volume":"29","author":"Thol","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2012.07.003_bib131","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3324\/haematol.2011.051532","article-title":"Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value","volume":"97","author":"Pratcorona","year":"2012","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.hoc.2012.07.003_bib132","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00277-011-1330-0","article-title":"TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms","volume":"91","author":"Martinez-Aviles","year":"2012","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.hoc.2012.07.003_bib133","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3324\/haematol.2011.045591","article-title":"Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes","volume":"96","author":"Stein","year":"2011","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.hoc.2012.07.003_bib134","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.hoc.2012.07.003_bib135","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","article-title":"IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication","volume":"28","author":"Paschka","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"10.1016\/j.hoc.2012.07.003_bib136","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1182\/blood-2010-02-267955","article-title":"IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status","volume":"116","author":"Schnittger","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2012.07.003_bib137","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.hoc.2012.07.003_bib138","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/leu.2010.77","article-title":"IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.hoc.2012.07.003_bib139","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/leu.2010.113","article-title":"IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.hoc.2012.07.003_bib140","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3324\/haematol.2010.025494","article-title":"IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis","volume":"95","author":"Thol","year":"2010","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.hoc.2012.07.003_bib141","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/leu.2010.52","article-title":"Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS\/myeloproliferative neoplasms","volume":"24","author":"Kosmider","year":"2010","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.hoc.2012.07.003_bib142","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/leu.2011.253","article-title":"IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F","volume":"26","author":"Tefferi","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.hoc.2012.07.003_bib143","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMc0910063","article-title":"Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms","volume":"362","author":"Green","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"7274","key":"10.1016\/j.hoc.2012.07.003_bib144","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"issue":"5924","key":"10.1016\/j.hoc.2012.07.003_bib145","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1126\/science.1170944","article-title":"Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha","volume":"324","author":"Zhao","year":"2009","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.hoc.2012.07.003_bib146","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"issue":"25","key":"10.1016\/j.hoc.2012.07.003_bib147","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","article-title":"DNMT3A mutations in acute myeloid leukemia","volume":"363","author":"Ley","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.hoc.2012.07.003_bib148","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/leu.2011.44","article-title":"Recurrent DNMT3A mutations in patients with myelodysplastic syndromes","volume":"25","author":"Walter","year":"2011","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.hoc.2012.07.003_bib149","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.3324\/haematol.2011.045559","article-title":"Rare occurrence of DNMT3A mutations in myelodysplastic syndromes","volume":"96","author":"Thol","year":"2011","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.hoc.2012.07.003_bib150","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/leu.2011.77","article-title":"DNMT3A mutations in myeloproliferative neoplasms","volume":"25","author":"Stegelmann","year":"2011","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.hoc.2012.07.003_bib151","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/leu.2011.82","article-title":"DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms","volume":"25","author":"Abdel-Wahab","year":"2011","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.hoc.2012.07.003_bib152","first-page":"2832","article-title":"Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2","volume":"118","author":"Bersenev","year":"2008","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"10.1016\/j.hoc.2012.07.003_bib153","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/blood-2007-05-089326","article-title":"Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders","volume":"110","author":"Gery","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2012.07.003_bib154","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1084\/jem.20040762","article-title":"Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis","volume":"200","author":"Tong","year":"2004","journal-title":"J\u00a0Exp Med"},{"issue":"12","key":"10.1016\/j.hoc.2012.07.003_bib155","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1182\/blood-2004-10-4093","article-title":"Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways","volume":"105","author":"Tong","year":"2005","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2012.07.003_bib156","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1084\/jem.20011883","article-title":"Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice","volume":"195","author":"Velazquez","year":"2002","journal-title":"J\u00a0Exp Med"},{"issue":"2","key":"10.1016\/j.hoc.2012.07.003_bib157","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1084\/jem.20011170","article-title":"Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk","volume":"195","author":"Takaki","year":"2002","journal-title":"J\u00a0Exp Med"},{"issue":"6","key":"10.1016\/j.hoc.2012.07.003_bib158","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood-2010-02-270108","article-title":"Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms","volume":"116","author":"Oh","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2012.07.003_bib159","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMc1006966","article-title":"LNK mutations in JAK2 mutation-negative erythrocytosis","volume":"363","author":"Lasho","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.hoc.2012.07.003_bib160","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/leu.2010.163","article-title":"LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.hoc.2012.07.003_bib161","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.4161\/cc.9.6.11034","article-title":"Gain-of-function c-CBL mutations associated with uniparental disomy of 11q in myeloid neoplasms","volume":"9","author":"Ogawa","year":"2010","journal-title":"Cell Cycle"},{"issue":"7","key":"10.1016\/j.hoc.2012.07.003_bib162","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00277-010-0920-6","article-title":"Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies","volume":"89","author":"Bacher","year":"2010","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.hoc.2012.07.003_bib163","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1182\/blood-2007-01-066076","article-title":"Flt3-dependent transformation by inactivating c-Cbl mutations in AML","volume":"110","author":"Sargin","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2012.07.003_bib164","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2006-12-061176","article-title":"Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia","volume":"110","author":"Caligiuri","year":"2007","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.hoc.2012.07.003_bib165","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1182\/blood-2008-12-194548","article-title":"Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms","volume":"113","author":"Grand","year":"2009","journal-title":"Blood"},{"issue":"7257","key":"10.1016\/j.hoc.2012.07.003_bib166","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature08240","article-title":"Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms","volume":"460","author":"Sanada","year":"2009","journal-title":"Nature"},{"issue":"36","key":"10.1016\/j.hoc.2012.07.003_bib167","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1200\/JCO.2009.23.7503","article-title":"Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies","volume":"27","author":"Makishima","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.hoc.2012.07.003_bib168","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2009.27.1361","article-title":"Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1","volume":"28","author":"Kohlmann","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2012.07.003_bib169","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3324\/haematol.2010.029306","article-title":"Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms","volume":"95","author":"Beer","year":"2010","journal-title":"Haematologica"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985881200127X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985881200127X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:57:56Z","timestamp":1760183876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985881200127X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":169,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S088985881200127X"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2012.07.003","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genotype-Phenotype Interactions in the Myeloproliferative Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2012.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}